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Background: This study analyzed prognostic factors and treatment outcomes of primary thyroid lymphoma.
Patients and Methods: Data were retrospectively collected for 87 patients (53 stage I and 34 stage II) with median
age 65 years. Fifty-two patients were treated with single modality (31 with chemotherapy alone and 21 with
radiotherapy alone) and 35 with combined modality treatment. Median follow-up was 51 months.
Results: Sixty patients had aggressive lymphoma and 27 had indolent lymphoma. The 5- and 10-year overall survival
(OS) rates were 74% and 71%, respectively, and the disease-free survival (DFS) rates were 68% and 64%. Univariate
analysis revealed that age, tumor size, stage, lymph node involvement, B symptoms, and treatment modality were
prognostic factors for OS, DFS, and local control (LC). Patients with thyroiditis had significantly better LC rates. In
multivariate analysis, OS was influenced by age, B symptoms, lymph node involvement, and tumor size, whereas DFS
and LC were influenced by B symptoms and tumor size. Compared with single modality treatment, patients treated
with combined modality had better 5-year OS, DFS, and LC.
Conclusions: Combined modality leads to an excellent prognosis for patients with aggressive lymphoma but does
not improve OS and LC in patients with indolent lymphoma.
Key words: chemotherapy, combined modality treatment, non-Hodgkin’s lymphoma, prognostic factors,
radiotherapy, thyroid lymphoma
introduction
Primary thyroid lymphoma (PTL) is a rare malignancy,
accounting for 2%–5% of all thyroid malignancies, 1%–2.5% of
all malignant lymphomas, and 2.5%–7% of all extranodal
lymphomas [1, 2]. PTL is predominantly seen in middle- to
older-aged women and usually presents as a painless mass in the
neck region requiring a biopsy for tissue diagnosis [3]. The
presence of B symptoms is uncommon [4]. The thyroid gland
contains no native lymphoid tissue although in autoimmune
thyroid disease, notably in Hashimoto’s thyroiditis, the thyroid
gland accumulates lymphatic cells [5]. The relative risk of
developing a malignant thyroid lymphoma has been estimated
to be 40–80 times greater in patients with Hashimoto’s
thyroiditis than in the general population, with lymphoma
typically manifesting 20–30 years after the diagnosis of
thyroiditis [6]. This evolution from Hashimoto’s thyroiditis to
lymphoma [typically a mucosa-associated lymphoid tissue
(MALT) lymphoma] occurs in 0.5% of cases and is generally
characterized by an indolent course. In some cases, however,
transformation from MALT lymphoma to aggressive lymphoma
may occur, with a poor prognosis [7]. Most thyroid lymphomas
are B-cell-type non-Hodgkin’s lymphomas (NHLs), and
Hodgkin’s and T-cell lymphomas are extremely rare [6].
The optimal strategy for managing PTL remains somewhat
controversial. Up to 20 years ago, local surgery was used as
a primary management strategy because of the difficulty in
distinguishing histologically between malignant lymphoma and
anaplastic thyroid carcinoma, especially based on preoperative
biopsy [8]. Now, diagnosis can be accomplished using fine-
needle aspiration biopsy (FNAB) or by core or open biopsy.
Although complete surgical resection improves prognosis over
incomplete resection [8, 9], malignant lymphomas are very
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treatment, either alone or in combination with chemotherapy
(ChT) [8, 10]. To diminish the likelihood of local and systemic
relapses, multiagent ChT, generally consisting of
cyclophosphamide, adriamycin, vincristine, and prednisone
(CHOP) and more recently including rituximab (R-CHOP),
followed by involved-field radiotherapy (IFRT), has become
more frequently used for aggressive lymphomas [11, 12].
Treatment with RT alone is typically reserved for cases with an
indolent histology [8, 13], whereas combined modality
treatment (CMT) with ChT and RT is preferred for aggressive
lymphomas. Due to its rarity, very few studies have investigated
the optimal treatment of PTL, and many reviews are based on
studies including small numbers of patients. The goal of this
Rare Cancer Network (RCN) study was to retrospectively
collect a sufficient number of patients to identify prognostic
factors that affect disease-free survival (DFS) and overall
survival (OS) in PTL patients.
materials and methods
patient characteristics
Between 1986 and 2006, 93 patients with PTL were treated in nine member
institutions of the RCN: China, 30 patients from one center; USA, 27
patients from one center; The Netherlands, 11 patients from one center;
Turkey, 13 patients from three centers; Greece, 7 patients from one center;
and Switzerland, 5 patients from two centers. Information on patient
demographics, clinical presentation, staging examinations, pathological
characteristics, treatment parameters, recurrence, survival outcomes, and
treatment-related morbidity was obtained. The inclusion criteria were
histologically proven NHL of the thyroid gland, localized disease, age ‡18
years, and minimum follow-up of 6 months. Only patients with lymphoma
primarily involving the thyroid gland were included. Eighty-seven patients
were eligible for the study and seven were excluded; three for incomplete
data, two did not finish the planned treatment schedule, and one with
secondary metastatic cancer.
Staging investigations included medical history and physical
examination, complete hematologic profile, blood chemistry, and chest
radiograph of all patients. The following tests were carried out: bone
marrow aspiration and biopsy (61%), thoracic computed tomography (CT)
(49%), erythrocyte sedimentation rate (43%), b2-microglobulin (36%),
and positron emission tomography scan (5%). Infradiaphragmatic staging
was carried out with abdominal CT (51%), abdominal ultrasonography
(38%), or both (11%). According to the Ann Arbor Classification [14], 53
patients (61%) were stage I and 34 (39%) were stage II.
The main findings were a painless, rapidly enlarging thyroid mass in 69
patients (79%) and aerodigestive tract symptoms, including dyspnea and
dysphagia, in 41 (47%). Six patients (7%) had thyroid enlargement together
with hypothyroidism. Lymphadenopathy was present in the neck in 20
patients (23%) and at the level of the mediastinum in 10 patients (11%); 4
patients (5%) had both cervical and mediastinal lymph node involvement.
FNAB was carried out in 8 patients (9%), core biopsy in 24 (28%), and
surgical excision in 55 (63%). In eight patients with FNAB, additional
immunohistochemical analysis was carried out for accurate diagnosis.
Patients were mostly diagnosed surgically at earlier dates with a substitution
toward biopsy in more recent patients. World Health Organization
classification was used to identify histological subtypes. The majority of
patients had diffuse large B-cell histopathology (56 patients; 64%), while
18 (21%) had MALT lymphoma, 9 (10%) had follicular lymphoma, and
4 (5%) had other lymphoma subgroups (2 lymphoblastic lymphomas,
1 T-cell lymphoma, and 1 mantle cell lymphoma).
treatment modalities
Fifty-five patients (64%) underwent thyroid resection: 42 (48%)
hemithyroidectomy and 13 (16%) total thyroidectomy. A tracheostomy was
required to relieve airway obstruction symptoms before treatment in eight
patients (9%). Surgery was carried out primarily for diagnosis, and all
patients with thyroid resection were treated postoperatively: 16 (19%) with
RT alone, 17 (20%) with ChT alone, and 22 (25%) with both RT and ChT
as CMT. Thirty-two patients (37%) were treated definitively with RT
(5 patients; 6%), ChT (12 patients; 14%), or CMT (15 patients; 17%).
Among the 66 patients (76%) receiving ChT (with or without RT and/or
surgery), 46 were treated with the CHOP regimen, 14 with CHOP and
rituximab, and 6 with other ChT regimens. The median number of ChT
cycles was seven (range 1–13).
For the 58 patients who received RT, the median dose was 40 Gy (range
20–54), with a median daily dose of 2 Gy (range 1.5–3). Thirty-four
patients received a radiation dose to the primary region of ‡40 Gy.
Radiation was delivered with a linear accelerator (6–8 MV) in 51 patients
and by 60Co gamma rays in the remaining 7 patients. Twenty patients were
treated with IFRT, including the thyroid bed and cervical lymph nodes, and
38 received extended-field radiotherapy (EFRT) that included thyroid,
cervical, and upper mediastinal lymph nodes. Treatment was delivered with
parallel opposing anterior–posterior fields: 38 patients were treated using
conventional techniques, 14 had two-dimensional treatment planning, and
6 had three-dimensional conformal RT.
Patients with follicular lymphoma were treated with single modality
therapy, either ChT (five patients; 56%) or RT (four patients; 46%).
Patients with other histological types had either single or combined
treatment modalities.
clinical end points and follow-up
This study analyzed OS as the primary end point. DFS was calculated from
the time of diagnosis to the time of first relapse for DFS and OS from
diagnosis to time of death or last follow-up. For DFS, treatment failure was
defined as any form of disease recurrence or death from any cause.
statistical analysis
The basic characteristics of patients with indolent and aggressive
lymphomas were compared using Fisher’s exact test. Survival curves were
obtained by the Kaplan–Meier method, and comparisons were made using
log-rank tests. Factors found to be significant by univariate analysis were
considered for multivariate analysis. Cox proportional hazards models were




The median follow-up was 51 months (range 6–239) for the
whole group and 76 months (range 6–239) for surviving
patients. Median age was 65 years (range 15–92) with
a male : female ratio of 1 : 2. Sixty patients (69%) had
aggressive lymphoma and 27 (31%) had indolent lymphoma,
either MALT lymphoma (18 patients; 21%) or follicular
lymphoma (9 patients; 10%). Characteristics of patients with
indolent and aggressive lymphomas are summarized in Table 1.
Majority of patients (53 patients; 61%) had stage I disease,
whereas 34 patients (39%) patients had stage II disease. Of 56
patients with diffuse large B-cell lymphoma (DLBCL), 35
patients (63%) had stage I and 21 patients (37%) had stage II
disease. Likewise, 10 of 18 patients with MALT lymphoma and
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6 of 9 patients with follicular lymphoma had stage I disease.
The remaining two patients with lymphoblastic lymphoma had
stage II disease, and one patient with T-cell lymphoma and one
with mantle cell lymphoma had stage I disease each.
A total of 65 patients (75%) were alive at last follow-up:
58 with no evidence of disease and 7 with disease. Twenty-two
patients (25%) died during follow-up; 15 from causes
related to PTL and 7 from other causes (2 with coronary
heart disease, 2 due to pneumonia, 1 after gastrointestinal
bleeding, 1 with tumor uterine sarcoma, and 1 due to an
unknown cause).
overall survival
The actuarial 5- and 10-year OS rates for the whole group were
74% and 71%, respectively (Figure 1). The 5- and 10-year OS
rates were 80% and 74%, respectively, for indolent lymphoma
and 73% and 71% for aggressive lymphoma. The prognostic
factors for OS on univariate and multivariate analyses are
summarized in Tables 2 and 3, respectively, whereas Tables 4
and 5 show univariate and multivariate analysis of prognostic
factors in indolent and aggressive lymphomas. For the whole
group, CMT significantly improved OS compared with single
modality with either ChT or RT (91% versus 57%, P = 0.01,
and versus 69%, P = 0.03, respectively) (Figure 3). There was no
significant difference between treatment with ChT or RT alone
(P = 0.8). In indolent lymphoma, CMT did not significantly
improve OS compared with single modality, and treatment
with either RT or ChT alone did not differ significantly (Table
4). In aggressive lymphoma, CMT significantly improved OS
compared with single modality treatment with RT alone (P =
0.005) or ChT alone (P = 0.02), although the results of
treatment with either RT alone or ChT alone did not differ
significantly (Table 5). There was a trend toward statistical
significance for higher RT doses (>40 Gy) compared with doses
£40 Gy (86% versus 73%, P = 0.09). On multivariate analysis, B
symptoms (P = 0.007), tumor size (P = 0.02), and lymph node
involvement (P = 0.02) were all found to be significant
prognostic factors for survival. Treatment modality was close to
the level of significance (P = 0.08).
local control
The crude local recurrence rate was 17% (15 of 87 patients, 12
of whom died of disease). The actuarial LC rates were 77% and
73% at 5 and 10 years, respectively. The results of univariate
analysis are summarized in Table 2. While CMT improved
5-year LC rates compared with either ChT or RT alone
(95% versus 56%, P < 0.001, and versus 69%, P = 0.001), single
treatment modality with either ChT or RT did not differ
significantly (P = 0.5). In patients treated with RT, doses ‡40
Gy significantly improved LC rates compared with lower RT
doses (94% versus 78%, P = 0.04), whereas EFRT did not
significantly improve LC compared with IFRT. On multivariate
analysis, a significantly worse LC was found for patients with
B symptoms [hazard ratio (HR) 3.7, P = 0.03] and for stage II
disease (HR 2.8, P = 0.04). Treatment modality did not
significantly improve LC.
disease-free survival
The 5- and 10-year actuarial DFS rates were 68% and 64%,
respectively (Figure 2). The 5- and 10-year DFS rates were 70%
and 67% for indolent lymphoma and 63% and 54% for
aggressive lymphoma. The prognostic factors affecting DFS are
summarized in Tables 2 and 3 for the whole population and in
Tables 4 and 5 according to indolent and aggressive
lymphomas. CMT significantly improved DFS compared with
ChT alone (P < 0.001) and RT alone (P < 0.001). The 5-year
DFS rate was 49% for ChT alone, 45% for RT alone, and 91%
for CMT (P = 0.04) (Figure 4). Treatment with ChT alone or
RT alone did not differ significantly (P = 0.2). DFS rates in
patients with indolent and aggressive lymphomas were
significantly better in the CMT arm (Table 3); however, there
was no difference between treatment with RT alone or ChT
alone in either indolent or aggressive lymphoma. In patients










Male 7 (26) 22 (37) 0.46
Female 20 (74) 38 (63)
Age (years)
£60 12 (44) 38 (63) 0.10
>60 15 (56) 22 (37)
Tumor size (cm)
<5 16 (59) 21 (35) 0.08
5–10 7 (26) 30 (50)
>10 4 (15) 8 (15)
Stage
I 16 (59) 37 (62) 0.81
II 11 (41) 23 (38)
Palpable mass
Absent 7 (26) 22 (37) 0.46
Present 20 (74) 38 (63)
B symptoms
Absent 24 (89) 55 (92) 0.39
Present 3 (11) 5 (8)
Thyroiditis
Absent 20 (74) 47 (78) 0.58
Present 7 (26) 13 (22)
Aerodigestive tract compression
Absent 16 (59) 29 (48) 0.36
Present 11 (41) 31 (52)
Lymph node involvement
Absent 3 (11) 9 (15) 0.86
Present 24 (89) 51 (85)
Treatment modality
Single modality 15 (56) 36 (60) 0.81
Combined modality 12 (44) 24 (40)
Treatment
ChT alone 9 (33) 21 (35) 0.87
RT alone 6 (22) 15 (25)
ChT and RT 12 (45) 24 (40)
ChT, chemotherapy; RT, radiotherapy.
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treated with RT, doses ‡40 Gy had borderline significance for
DFS compared with lower RT doses (94% versus 76%, P =
0.05). Patients treated with EFRT had higher DFS compared
with patients treated with IFRT (93% versus 67%, P = 0.01). On
multivariate analysis, presence of B symptoms (P = 0.001), large
tumor (P = 0.02), and single modality treatment (P = 0.01)
were found to be negative significant prognostic factors for DFS
(Table 3). Although lymph node involvement did not show
significance on LC, there was a trend toward a negative impact
(HR 3.3, 95% confidence interval 1.0–11.3, P = 0.05).
patterns of relapse
Locoregional and distant relapse was seen in 15 patients (17%)
and 9 patients (10%), respectively, while 2 patients (2%)
presented with both locoregional and distant relapse. Distant
relapses were mainly seen in the abdomen (six patients), with
two patients having either pulmonary relapse or paranasal sinus
relapse.
early and late toxic effects
Due to the retrospective nature of the study and because data
were collected from different centers, early and late toxic effects
were assessed only through patient chart review and cannot be
considered a complete assessment of toxicity. Eighteen patients
(21%) had grade 2 and two (2%) had grade 3 acute toxicity,
including dysphagia, dyspnea, and skin reactions. Severe late
(grade 3–4) effects included clinical hypothyroidism (seven
patients), neck fibrosis (one patient), hemiparesis (one patient),
polyneuropathy and lung fibrosis (one patient), pneumonia
(one patient), and brain necrosis and abscess (one patient).
Infield secondary cancer (papillary thyroid cancer and breast
cancer) was observed in two patients.
discussion
Our data from patients treated for PTL over a prolonged period
of time provide valuable insight into the management of this
uncommon disease. Although published results from smaller
series failed to isolate significant prognostic factors, we
collected enough data to identify several factors that have
prognostic value with respect to OS, DFS, and LC. We also
demonstrated the superiority of CMT for DFS and LC in all
subgroups and for OS for patients with aggressive lymphoma.
PTL is most commonly observed in middle-to older-aged
females [15]. The main presenting findings are a mass in the
thyroid gland or diffuse enlargement that causes symptoms
related to compression, such as hoarseness, dysphagia, and
dyspnea. The majority of our patients (68 of 86) had thyroid
enlargement at diagnosis. Age has been shown to be
a significant factor determining OS rates among PTL patients,
especially those >60 years of age, in agreement with our results
[15, 16].
Approximately 80% of patients with thyroid lymphoma
present with stage I or II disease [2, 15]. Although the staging
for NHL is adopted from the Ann Arbor system, difficulties and
controversies can arise in staging especially extranodal NHL
[17]. In view of this, Dawson et al. [18] proposed that specific
staging of primary NHL at any extranodal site should be
restricted to disease with the main manifestation at the
extranodal site, with or without regional lymph node
involvement. This essentially limits the staging of primary NHL
of the thyroid gland to stage I or II disease [18]. For this reason,
in our study, stage I patients had localized involvement of the
thyroid only, whereas in stage II patients the major site of
involvement was the thyroid gland but associated with regional
lymph node involvement.
Figure 1. Overall survival of the total patient group.
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Table 2. Univariate analysis of prognostic factors for OS, LS, and DFS
Factor n (%) 5-Year OS (%) P 5-Year LC (%) P 5-Year DFS (%) P
Age (years)
£60 29 (33) 84 0.02 85 0.2 78 0.8
>60 58 (67) 66 71 65
Sex
Male 37 (43) 68 0.6 74 0.7 61 0.7
Female 50 (57) 77 79 71
Pathology
Aggressive 60 (69) 73 0.8 74 0.7 63 0.8
Indolent 27 (31) 80 79 70
Tumor size (cm)
<5 38 (44) 88 0.01 87 0.03 77 0.01
5–10 38 (44) 70 77 68
>10 11 (12) 46 47 36
Stage
I 53 (61) 80 0.02 91 0.001 75 0.02
II 34 (39) 65 56 55
Lymph node involvement
Absent 10 (12) 81 0.01 78 0.03 79 0.03
Present 77 (88) 50 54 55
Palpable mass
Absent 28 (32) 80 0.3 83 0.3 79 0.2
Present 59 (68) 71 75 69
B symptoms
Absent 81 (93) 79 <0.0001 82 <0.0001 76 <0.0001
Present 6 (7) 33 31 25
Thyroiditis
Absent 66 (76) 70 0.4 62 0.02 65 0.1
Present 21 (24) 87 83 80
Aerodigestive compression
Absent 46 (53) 77 0.4 78 0.4 76 0.4
Present 41 (47) 71 73 68
Treatment modality
Single modality 50 (58) 61 0.009 62 0.001 53 0.008
Combined modality 37 (42) 92 95 83
Treatment
ChT alone 21 (24) 57 0.01 56 0.001 49 0.04
RT alone 29 (33) 69 69 63
ChT and RT 37 (43) 91 95 91
OS, overall survival; LC, local control; DFS, disease-free survival; ChT, chemotherapy; RT, radiotherapy.
Table 3. Multivariate analysis of prognostic factors for OS (Cox model)
Factor OS exp(B) [95% CI
for exp(B)]
DFS exp(B) [95% CI
for exp(B)]
LC exp(B) [95% CI
for exp(B)]
B symptoms (present versus
absent)
4.2 [1.7–13.0], P = 0.002 5.6 [1.9–16.6], P = 0.003 3.6 [1.1–11.6], P = 0.04
Tumor size (<5 versus ‡5 cm) 2.4 [1.2–5.4], P = 0.03 2.1 [1.3–4.1], P = 0.03 1.8 [0.7–4.0], P = 0.2
Stage (I versus II) 1.2 [0.4–3.6], P = 0.6 1.8 [0.8–4.9], P = 0.09 2.5 [1.1–7.6], P = 0.04
Lymph node involvement
(present versus absent)




2.9 [0.9–10.6], P = 0.08 4.2 [1.3–16.1], P = 0.03 3.8 [1.1–19.8], P = 0.1
OS, overall survival; CI, confidence interval; DFS, disease-free survival; LC, local control.
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PTL is predominantly of B-cell origin and is commonly
associated with Hashimoto’s thyroiditis. Williams et al. [19]
reported a causal relationship between Hashimoto’s thyroiditis
and development of lymphoma, although other studies do not
support this [20, 21]. Although worse outcomes have been
reported for malignant lymphomas arising from autoimmune
disease, this is not supported by our findings or some other
studies [20, 21]. Belal et al. [20] demonstrated relapse-free
survival rates of 94% in patients with preexisting thyroiditis
compared with 47% in patients without known thyroiditis;
however, in our series, we found that DFS, OS, and LC rates
were better in patients with preexisting thyroiditis, which may
be attributable of coexistence of thyrioditis with MALT
lymphoma and DLBCL related to MALT lymphoma, which has
an indolent behavior than DLBCL. Since there exists an
observed association with MALT lymphoma and thyroiditis in
a substantial number of cases, it is unfortunately difficult to
differentiate the reason of hypothyroidism seen in our seven
cases, either treatment-related or preexisting thyroiditis.
Although hypothyroidism seen after treatment, this condition
is relatively easy to manage. Most thyroid lymphomas are
DLBCL, although up to 25% of the lesions may be indolent
lymphomas, including follicular lymphoma and MALT
lymphoma. The most common B-cell lymphoma is the diffuse
Table 4. Univariate analysis of prognostic factors for OS and DFS
among indolent and aggressive lymphoma
Features Indolent lymphoma Aggressive lymphoma
P P
OS DFS OS DFS
Age 0.02 0.008 0.24 0.91
Sex 0.21 0.67 0.81 0.97
Tumor size 0.02 0.01 0.03 0.02
Stage 0.11 0.05 0.07 0.03
Lymph node involvement <0.001 <0.001 <0.001 <0.001
Palpable mass 0.47 0.54 0.81 0.76
B symptoms 0.01 0.009 <0.001 <0.001
Thyroiditis 0.51 0.25 0.39 0.56
Aerodigestive compression 0.91 0.42 0.47 0.67
OS, overall survival; DFS, disease-free survival.
Table 5. Multivariate analysis of prognostic factors for OS and DFS by Cox proportional hazards analysis
Prognostic factors OS exp(B) [95% CI for exp(B)] DFS exp(B) [95% CI for exp(B)]
Indolent Aggressive Indolent Aggressive
Age (>60 years) 5.7 [0.5–31.7], P = 0.2 1.9 [0.5–6.1], P = 0.3 7.0 [1.1–25.5], P = 0.04 1.2 [0.7–2.2], P = 0.4
B symptoms 3.3 [0.4–25.0], P = 0.4 7.8 [1.4–22.9], P = 0.02 3.6 [0.5–22.6], P = 0.3 10.1 [1.9–34.5], P = 0.007
Tumor size (‡5 cm) 2.1 [0.4–10.7], P = 0.4 2.4 [0.9–6.6], P = 0.09 1.7 [0.6–4.9], P = 0.4 2.1 [0.9–4.7], P = 0.08
Stage II 2.5 [0.4–10.6], P = 0.4 1.2 [0.3–4.7], P = 0.7 2.5 [0.5–11.7], P = 0.2 1.1 [0.3–3.9], P = 0.8
Treatment modality 1.6 [0.7–15.4], P = 0.7 4.3 [1.9–10.0], P = 0.04 3.1 [0.4–18.1], P = 0.4 5.4 [1.2–15.5], P = 0.03
OS, overall survival; CI, confidence interval; DFS, disease-free survival.
Figure 2. Disease-free survival of the total patient group.
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Figure 4. Disease-free survival according to treatment modality.
Figure 3. Overall survival according to treatment modality.
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large cell accounting for 50%–70% of all lymphomas, as was in
our series [21–23]. Other rare subtypes include follicular
lymphoma (12%), Hodgkin’s disease (7%), small lymphocytic
lymphoma (4%), and Burkitt’s lymphoma (4%). Thyroid
DLBCL at a localized stage generally has a good prognosis, but
it is heterogeneous with respect to the pathological subtype and
some types have a poor prognosis [24, 25]. MALT is recognized
as a distinct lymphoma with unique clinicopathologic features.
MALT lymphomas generally arise in lymphoid tissue that has
developed as a result of chronic inflammation, such as seen in
Hashimoto’s thyroiditis. Pure MALT lymphomas of the thyroid
make up 23%–30% of primary lymphomas [21, 26]. The
incidence of aggressive lymphomas was 96% in the series of
Rosen et al. [27] and 100% in that of Belal et al. [20], and
several other studies have reported a similar incidence [13, 15,
22]. In our series, 36% of patients had indolent lymphoma,
which seems higher than previously published findings. The
recruitment of patients mainly through radiation oncology
departments may have led to an overrepresentation of these
cases. Unfortunately, the treatment results of indolent
lymphoma were found to be worse than those in other
anatomical sites, and further research is needed to determine
whether there is a distinct biological background of PTL.
Because of the rarity of PTL, no randomized controlled trials
have compared the efficacy of multimodality versus single
modality treatment. In a retrospective series by Ha et al. [28],
they found that the 5-year OS and DFS rates are 64% and 76%,
which is in concordance with our findings. And they concluded
that prognosis for patients with localized NHL involving the
thyroid gland have good outcome, especially when CMT was
used. However, it seems reasonable to extrapolate treatment of
this disease based on the results of randomized trials for other
sites of nodal and extranodal lymphoma. In the Eastern
Cooperative Oncology Group 1484 study, Horning et al. [29]
demonstrated improved DFS in 172 patients with early-stage
aggressive lymphoma treated with CHOP and low-dose RT (30
Gy) but without any OS benefit. In a multicenter trial of 401
similar patients, Miller et al. [30] reported a 5-year progression-
free survival of 77% for CHOP plus RT versus 64% for CHOP
alone and an estimated 5-year OS of 82% versus 72%, and
CMT has subsequently been considered the standard of care for
early-stage aggressive lymphomas. In a review of 211 patients
with thyroid lymphoma, Doria et al. [31] demonstrated that
addition of ChT to RT significantly lowered distant and overall
recurrence rates compared with RT alone (overall recurrence
8% versus 37%; distant recurrence 5% versus 31%). Our
findings clearly demonstrated that CMT significantly improved
DFS, OS, and LC for aggressive lymphoma and DFS and LC for
other types of lymphoma (Table 6). Similar to published
findings, the addition of rituximab, a chimeric anti-CD20
immunoglobulin G1 monoclonal antibody, to CHOP improved
OS (92% versus 71%, P = 0.06) [11, 12, 32, 33].
Given the retrospective nature of our review (i.e.
retrospective, multi-institutional study over the years, many
pathologists) and variation in the treatment methods
employed, patient selection bias may have impacted the results
of our study. However, all patients were treated with
conventionally fractionated RT and conventional ChT, and
relatively few patients received single modality treatment.
Without data from randomized studies, the results of
retrospective reviews such as ours provide a valuable
contribution to our understanding of the clinical behavior and
treatment of PTL. Based on the results of our retrospective
series and extrapolated evidence of two randomized controlled
trials for mainly nodal aggressive lymphomas [29, 30], we
recommend CMT for the treatment of PTL. The use of better
staging procedures, improvement of ChT by the addition of
rituximab to CHOP, limited use of surgery, and advanced RT
delivery techniques will improve results for patients with PTL
with respect to DFS and side-effects.
conclusions
Since PTL is a rare disease, it is difficult to carry out prospective
randomized trials to evaluate prognostic factors and optimal
treatment combinations. Our multivariate analysis of data
obtained from a large number of patients identified the
following independent prognostic factors: age, B symptoms,
lymph node involvement, and treatment modality for OS; B
symptoms and treatment modality for DFS; and B symptoms,
lymph node involvement, and treatment modality for LC.
Patients with aggressive lymphoma are good candidates for
CMT involving ChT and RT.
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